Crucell N.V. (CRXL) Announces PER.C6 Licensing Agreement With Vascular Biogenics Ltd.
10/19/2005 5:13:10 PM
LEIDEN, The Netherlands, March 30, 2005 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that it has signed a PER.C6(R) research license agreement with Israeli biopharmaceutical company Vascular Biogenics Ltd. The non-exclusive agreement allows Vascular Biogenics to use the PER.C6(R) cell line for the preparation and evaluation of gene therapeutics based on adenoviral vectors.
comments powered by